The DOI matches its Crossref record; 46 of the 51 references it cites were found in a registry or an index.
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
Open accessAbstract
BACKGROUND: Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. METHODS: One study tested pemetrexed versus docetaxel in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced NSCLC. Cox proportional hazard models were used to test for covariate-adjusted treatment-by-histology interactions (THIs) for overall survival (OS) and progression-free survival (PFS). For each histologic subgroup, the Kaplan-Meier method was used to estimate unadjusted within-arm medians, and Cox models were used to estimate covariate-adjusted between-arm hazard ratios (HRs). RESULTS: In both studies, treatment arms were well balanced for histology. THIs were statistically significant (p < .005) for both OS and PFS. Nonsquamous patients treated with pemetrexed-based therapy experienced longer survival than the comparators (HR, 0.78 and 0.84, respectively), whereas squamous patients had shorter survival (HR, 1.56 and 1.23, respectively). Whereas the efficacy of pemetrexed regimens differed according to histology, it did not differ for docetaxel or for cisplatin plus gemcitabine. Pemetrexed was well tolerated across histologic groups. CONCLUSIONS: The consistency of these results across studies confirms the predictive effect of histology for pemetrexed and the survival advantage for pemetrexed in patients with nonsquamous histology. These analyses suggest pemetrexed should not be recommended for the treatment of squamous cell carcinoma, but, because of efficacy and safety advantages, pemetrexed may be preferable to other agents for treatment of patients with nonsquamous NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a retrospective analysis, a predictive impact of histology on outcome by pemetrexed was reported favouring those patients with NSCC (median OS: 8.0 versus 9.3 months, docetaxel versus pemetrexed, HR 0.78, 95% CI: 0.61-1.0,P = 0.004) [56].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,524
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationScagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citationFukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Self-citationThatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Research works printed but not linked: 2
- Jiroutek, 1998, Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981–1992, Proc Am Soc Clin Oncol, 17, 461a
- National Cancer Institute, 1999, Common Toxicity Criteria v2.0 (CTC)
Cited by
Sorted by citations
Items 401–500 of 687
Vergnenégre, A., Smit, E. F., Toy, E., Parente, B., Schmitz, S. H., Kraaij, K., Soldatenkova, V., Visseren‐Grul, C., Zanotti, G., Taipale, K., et al. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.703133 · Cited by 10
Diagnostic Workup of Lung Cancer
Sugarbaker, D. J., & DaSilva, M. C. (2011) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2011.08.003 · Cited by 10
Davies, J. M., Dhruva, N., Walko, C. M., Socinski, M. A., Bernard, S. A., Hayes, D. N., Kim, W. Y., Ivanova, A., Keller, K., Hilbun, L. R., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.05.022 · Cited by 10
Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy
Wu, X., & Huang, X. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.2.647 · Cited by 10
Lü, S., Cheng, Y., Zhou, C., Wang, J., Yang, J. C., Zhang, P.-H., Zhang, X., Wang, X., Orlando, M., & Wu, Y.-L. L. C. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.04.003 · Cited by 10
The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update
Matikas, A., Georgoulias, V., & Kotsakis, A. P. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1240620 · Cited by 10
Kotake, M., Miura, Y., Imai, H., Mori, K. P., Sakurai, R., Kaira, K., Tomizawa, Y., Minato, K., Saito, R., & Hisada, T. (2017) · Chemotherapy · doi:10.1159/000456534 · Cited by 10
Perzanowska, A., Fatalska, A., Wojtas, G., Lewandowicz, A., Michalak, A., Krasowski, G., Borchers, C. H., Dadlez, M., & Domański, D. (2018) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201700084 · Cited by 10
Chan, S.-K., Choi, C., & Lee, V. H.-F. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100322 · Cited by 10
Chang, G.-C., Myung‐Ju, A. H. N., Wright, E. J., Kim, H. T., Joo‐Hang, K. I. M., Kang, J. H., Sang‐We, K. I. M., Sherman, S. A., & Walzer, S. (2011) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2011.01400.x · Cited by 10
Reaume, M. N., Leighl, N. B., Mittmann, N., Coyle, D., Hirsh, V., Seymour, L., Tu, D., Shepherd, F. A., Graham, B., Gridelli, C., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.012 · Cited by 10
Self-citationMotesanib and advanced NSCLC: experiences and expectations
Raghav, K. P. S., & Blumenschein, G. R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.579103 · Cited by 10
Developments in pharmacotherapy for treating metastatic non-small cell lung cancer
Rossi, A., Sacco, P. C., Santabarbara, G., Sgambato, A., Casaluce, F., Palazzolo, G., Maione, P., & Gridelli, C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1280460 · Cited by 10
Real-World Diagnostic Accuracy and Use of Immunohistochemical Markers in Lung Cancer Diagnostics
Lindquist, K. E., Gudinavičienė, I., Mylona, N., Urdar, R., Lianou, M., Darai‐Ramqvist, E., Haglund, F., Béndek, M., Bardóczi, E., Dobra, K., et al. (2021) · Biomolecules · doi:10.3390/biom11111721 · Cited by 9
Liang, Y., Shao, Y., Liao, B.-C., Lee, H.-S., Yang, J. C., Chen, H., Chiang, C., Cheng, A., & Lai, M. (2016) · Journal of Cancer · doi:10.7150/jca.15180 · Cited by 9
Gaschler‐Markefski, B., Sikken, P., Heymach, J. V., Gottfried, M., Mellemgaard, A., Novello, S., Gann, C.-N., Barrueco, J., Reck, M., Hanna, N. H., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000102 · Cited by 9
Self-citationGridelli, C., Rossi, A., Maione, P., Ambrosio, R., Barbato, V., Bareschino, M. A., Schettino, C., Palazzolo, G., & Sacco, P. C. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.049 · Cited by 9
How close are we to customizing chemotherapy in early non-small cell lung cancer?
Ioannidis, G., Georgoulias, V., & Souglakos, J. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011409973 · Cited by 9
Sun, J., Oh, D., Lee, S., Kim, D., Im, S., Kim, T., Lee, J. S., Kim, Y.-W., Heo, D. S., & Bang, Y. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.07.013 · Cited by 9
In Vitro Effect of Neopterin on Erythropoiesis in Mice
Tsuboi, I., Hokari, T., Harada, T., Yuda, M., & Aizawa, S. (2009) · Pteridines · doi:10.1515/pteridines.2009.20.1.115 · Cited by 9
Skouras, V. S., Maragkos, C., Grapsa, D., & Syrigos, K. N. (2016) · BioDrugs · doi:10.1007/s40259-016-0194-1 · Cited by 10
Connock, M. J., Armoiry, X., Tsertsvadze, A., Meléndez‐Torres, G. J., Royle, P., Andronis, L., & Clarke, A. (2019) · BMC Cancer · doi:10.1186/s12885-019-5507-6 · Cited by 9
Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival
Chen, R.-L., Zhou, J.-X., Cao, Y., Sun, L.-L., Su, S., Deng, X.-J., Lin, J.-T., Xiao, Z.-W., Chen, Z.-Z., Wang, S., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01933 · Cited by 9
McHugh, C. I., Thipparthi, M., Lawhorn‐Crews, J. M., Polin, L., Gadgeel, S. M., Akoury, J., Mangner, T. J., Douglas, K. A., Li, J., Ratnam, M., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.207258 · Cited by 9
Cao, H., Zhu, W., Tang, H., Deng, C., Fu, F., Li, Y., Zhang, Y., & Chen, H. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.09.020 · Cited by 8
Herpel, E., Schnabel, P. A., Steins, M. B., Dienemann, H., Herth, F. J. F., Thomas, M., Schirmacher, P., & Warth, A. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04248.x · Cited by 8
Safety and Efficacy of Pemetrexed in Maintenance Therapy of Non-Small Cell Lung Cancer
Velez, M., Arango, B. A., Perez, C. A., & Santos, E. S. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s6248 · Cited by 8
Deng, L., Yang, J., Ren, T., Jing, M., Han, T., Zhang, B., & Zhou, J. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-22-1206 · Cited by 8
Selvam, M., Sadanandan, A., Chandrasekharan, A., Ramesh, S., Murali, A., & Krishnamurthi, G. (2024) · Scientific Reports · doi:10.1038/s41598-024-83786-6 · Cited by 11
Factors Influencing a Specific Pathologic Diagnosis of Non–Small-Cell Lung Carcinoma
Sulpher, J. A., Owen, S. P., Hon, H., Tobros, K., Shepherd, F. A., Sabri, E., Gomes, M. M., Sekhon, H. S., Liu, G., Canil, C. M., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.11.004 · Cited by 8
Self-citationMartinez, R. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2018.12.003 · Cited by 8
Buti, S., Bordi, P., Tiseo, M., Bria, E., Sperduti, I., Maïo, M. D., Panni, S., Novello, S., Rapetti, S. G., Pilotto, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.03.016 · Cited by 8
Zugazagoitia, J., Puente, J., González-Larriba, J. L., Manzano, A., Sotelo, M. J., Hernández, S., Sanz, J., Pérez, P., & Díaz‐Rubio, E. (2013) · Oncology · doi:10.1159/000346534 · Cited by 8
Oikawa, T., Ohira, T., Matsubayashi, J., Konaka, C., & Ikeda, N. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.03.007 · Cited by 8
Galetta, D., Rossi, A., Pisconti, S., Millaku, A., & Colucci, G. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70017-7 · Cited by 8
Systemic treatment of non-small-cell lung cancer
Lal, R., Enting, D., & Kristeleit, H. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70209-x · Cited by 8
The place of pemetrexed in the management of non-small-cell lung cancer patients
Tomasini, P., Greillier, L., Khobta, N., & Barlési, F. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.171 · Cited by 8
Carter, C. A., Zeman, K. G., Day, R. M., Richard, P., Oronsky, A. L., Oronsky, N. C., Lybeck, M., Scicinski, J. J., & Oronsky, B. T. (2016) · Oncotarget · doi:10.18632/oncotarget.8205 · Cited by 8
Suzuki, S., Karayama, M., Inui, N., Fujisawa, T., Enomoto, N., Nakamura, Y., Kuroishi, S., Matsuda, H., Yokomura, K., Koshimizu, N., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0365-4 · Cited by 8
Shiran, I., Heller, E., Jessel, S., Kamer, I., Daniel‐Meshulam, I., Navon, R., Urban, D., Onn, A., & Bar, J. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.01.009 · Cited by 8
Tang, H., Wang, H., Xi, S., He, C., Chang, Y., Wang, Q., & Wu, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s160565 · Cited by 8
Wang, F., Molina, J. R., Satele, D., Yin, J., Lim, V.-S., & Adjei, A. A. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0690-x · Cited by 8
Maintenance therapy for NSCLC: Consensus and controversy
Lü, S., & Yu, Y. (2011) · Chinese Journal of Cancer Research · doi:10.1007/s11670-011-0254-5 · Cited by 7
Powrózek, T., Kowalski, D. M., Krawczyk, P. A., Ramlau, R., Kucharczyk, T., Kalinka‐Warzocha, E., Knetki‐Wróblewska, M., Winiarczyk, K., Dyszkiewicz, W., Krzakowski, M. J., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.06.009 · Cited by 7
Shi, J., Chen, G., Wang, H., Wang, X., Han, B., Li, K., Wang, Q., Zhang, L., Wang, Z., Cheng, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14076 · Cited by 7
Hall, P. E., Spicer, J. F., & Popat, S. (2015) · Future Oncology · doi:10.2217/fon.15.110 · Cited by 7
The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial
Gridelli, C., & Maïo, M. D. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903485672 · Cited by 7
Kim, Y. H., Nishimura, T., Ozasa, H., Nagai, H., Sakamori, Y., Iwata, T., Sunadome, H., Nishimura, T., & Mishima, M. (2013) · Chemotherapy · doi:10.1159/000363731 · Cited by 7
Hata, A., Katakami, N., Fujita, S., Nanjo, S., Takeshita, J., Tanaka, K., Kaneda, T., Nishiyama, A., Nishimura, T., Nakagawa, A., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2755-2 · Cited by 7
Álvarez-Fernández, C., Perez, Q., Ruiz-Echeverria, L., Rubí, D. R., Sánchez‐Lorenzo, L., Torres, W. L., Izquierdo-Manuel, M., Berros, J. P., Luque-Cabal, M., Jiménez‐Fonseca, P., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9992-1 · Cited by 7
Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials
Shum, E., Wang, F., Kim, S., Perez-Soler, R., & Cheng, H. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1302425 · Cited by 7
Treatment paradigms in advanced non-small-cell lung cancer.
McCoach, C. E., & Kelly, K. L. (2013) · PubMed · Cited by 7
Pas, T. M. D., Toffalorio, F., Giovannetti, E., Radice, D., Russo, F. P., Angeli, I., Calamai, G., Spitaleri, G., Catania, C., Noberasco, C., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820d7818 · Cited by 7
Suzuki, A. S., Maemondo, M., Sugawara, S., Nakagawa, T., Taima, K., Inoue, A., Matsuno, K., Usui, K., Yokoi, T., Kanbe, M., et al. (2017) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2017.05.004 · Cited by 6
Liu, X., Zou, Q., Sun, Y., Liu, H., & Gao, C. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20180 · Cited by 7
Abbasi, M., Jahani, S., Biroudian, S., Boroujeni, M. A., Maghfoury, F., Aminizadeh, M., Malekyan, L., Faramarzpoor, H. R., & Foroughi, M. M. (2023) · RSC Advances · doi:10.1039/d3ra03983h · Cited by 6
Odabaş, H., Ulaş, A., Aydın, K., İnanç, M., Aksoy, A., Yazılıtaş, D., Türkeli, M., Yuksel, S., İnal, A., Ekinci, A., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3728-0 · Cited by 6
First-Line Therapeutic Options for Advanced Non-Small-Cell Lung Cancer in the Molecular Medicine Era
Capelletto, E., Novello, S., & Scagliotti, G. V. (2014) · Future Oncology · doi:10.2217/fon.13.247 · Cited by 6
Self-citationKim, H.-R., Kang, M. S., Na, I. I., Yang, S. H., Choi, Y. H., Kang, H. J., Kim, C. H., & Lee, J. C. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0687-0 · Cited by 6
Pilotto, S., Peretti, U., Novello, S., Rossi, G., Milella, M., Levra, M. G., Ciuffreda, L., Massari, F., Brunelli, M., Tortora, G., et al. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.778828 · Cited by 7
Takemoto, S., Nakamura, Y., Fukuda, M., Senju, H., Gyotoku, H., Taniguchi, H., Shimada, M., Ikeda, T., Yamaguchi, H., Nakatomi, K., et al. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12483 · Cited by 6
Capelle, H., Tummino, C., Greillier, L., Gouitaa, M., Birnbaum, J., Ausias, N., Barlési, F., & Montana, M. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12645 · Cited by 6
Post-chemotherapy and targeted therapy imaging of the chest in lung cancer
Carter, B. W., Altan, M., Shroff, G. S., Truong, M. T., & Vlahos, I. (2021) · Clinical Radiology · doi:10.1016/j.crad.2021.08.001 · Cited by 6
Jalal, S. I., Guo, A., Ahmed, S., & Kelley, M. J. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.014 · Cited by 6
Wang, Z. (2014) · Europe PMC (PubMed Central) · Cited by 6
Un regard simple sur la biologie moléculaire du cancer bronchique : la thymidylate synthase (TS)
Rouquette, I., & Mazières, J. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2010.12.009 · Cited by 6
Time to shift the burden of proof for oncogene-positive cancer?
Doebele, R. C. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.135 · Cited by 6
Quinton, C. L., & Ellis, P. M. (2011) · Cancers · doi:10.3390/cancers3033506 · Cited by 6
Targeted Therapies for Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung
Stinchcombe, T. E. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0256-2 · Cited by 6
Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review
Miller, D. S., Tai, D. F., Obasaju, C. K., & Vergote, I. B. (2013) · Modern Chemotherapy · doi:10.4236/mc.2013.22004 · Cited by 6
Trani, L., Myerson, J., Ashley, S., Young, K., Sheri, A., Hubner, R. A., Puglisi, M., Popat, S., & O'Brien, M. E. R. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.02.003 · Cited by 6
Lan, G., Lin, L., Chen, X., Chen, X., & Chen, X. (2017) · Medical Science Monitor · doi:10.12659/msm.904836 · Cited by 6
Indian Cooperative Oncology Network (ICON) (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_136_17 · Cited by 6
Patil, T., Nie, Y., Aisner, D. L., & Camidge, D. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.788245 · Cited by 6
Pang, L., Gan, J., Huang, Y., Liao, J., Lv, Y., Ali, W. A. S., Zhang, L., & Fang, W. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057098 · Cited by 6
Tomita, Y., Oguri, T., TAKAKUWA, O., Nakao, M., Kunii, E., Uemura, T., Ozasa, H., Miyazaki, M., Maeno, K., & Sato, S. (2011) · Oncology Letters · doi:10.3892/ol.2011.507 · Cited by 6
Shimizu, T., Nakagawa, Y., Asai, Y., Tsujino, I., Takahashi, N., & Gon, Y. (2019) · Journal of International Medical Research · doi:10.1177/0300060519852202 · Cited by 6
Non-Small Cell Lung Cancer: The Challenges of the Next Decade
Chevalier, T. L. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00029 · Cited by 6
Zhang, J., Zhang, X., Zhong, Y., Wang, J., Zhong, C., Xiao, M., Chen, Y., & Zhang, H. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07069-6 · Cited by 5
Ancillary Studies, Including Immunohistochemistry and Molecular Studies, in Lung Cytology
Schmitt, F. C., & Machado, J. C. (2013) · Surgical pathology clinics · doi:10.1016/j.path.2013.10.005 · Cited by 6
Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer
Rothschild, S. I., Gautschi, O. P., Lara, P. N., Mack, P. C., & Gandara, D. R. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328341ee38 · Cited by 5
Pennella, E. J., Obasaju, C. K., Pohl, G. M., Peltz, G., Girvan, A. C., Winfree, K. B., Martinez, B., Marciniak, M. D., Walker, M. S., Stepanski, E. J., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.06.011 · Cited by 5
Is Histologic Subtype Significant in the Management of NSCLC
Kotsakis, A. P., Yousem, S. A., & Gadgeel, S. M. (2010) · The Open Lung Cancer Journal · Cited by 5
Aktualisierte Therapieempfehlung metastasiertes nicht kleinzelliges Lungenkarzinom
Reinmuth, N., Gröschel, A., Schumann, C., Sebastian, M., Wiewrodt, R. G., & Reck, M. (2017) · Pneumologie · doi:10.1055/s-0043-118904 · Cited by 6
Subtyping of pulmonary adenocarcinoma in cytologic specimens
Moreira, A. L. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21313 · Cited by 5
Berge, E. M., & Doebele, R. C. (2013) · Drugs · doi:10.1007/s40265-013-0032-4 · Cited by 5
Second-line treatment options in advanced non-small cell lung cancer
de Marinis, F., & Ricciardi, S. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70172-1 · Cited by 5
Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer
Vincent, M. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00320 · Cited by 6
Gridelli, C., Rossi, A., & Maione, P. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70171-x · Cited by 5
Pankaj, G., Batra, U., Doval, D. C., Jain, P., Amitabh, U. K., Dash, P. K., Akhil, J., Mohit, A., & Bajaj, R. (2016) · South Asian Journal of Cancer · doi:10.4103/2278-330x.195345 · Cited by 5
Sakurada, T. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.18-00141 · Cited by 5
Halvorsen, T. O., Stokke, K., Killingberg, K. T., Raj, S. X., Sørhaug, S., Brustugun, O. T., Fløtten, Ø., Helbekkmo, N., Hornslien, K., Madebo, T., et al. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1778179 · Cited by 5
Grossi, F., Jaśkiewicz, P., Ferreira, M., Czyżewicz, G., Kowalski, D., Ciuffreda, L., Garcia-Gomez, R., Caruso, S., Bosch-Barrera, J., Gautier, S., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211022905 · Cited by 5
Diagnostic Patterns of Non-Small-Cell Lung Cancer at Princess Margaret Cancer Centre
Nadjafi, M., Sung, M., Santos, G. D. C., Le, L. W., Hwang, D., Tsao, M., & Leighl, N. B. (2020) · Current Oncology · doi:10.3747/co.27.5757 · Cited by 5
The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer
Tucker, S. J. (2009) · Current Drug Targets · doi:10.2174/138945010790031036 · Cited by 5
Lee, K. H., Choi, C., Kim, S., Suh, C., & Lee, J. (2011) · Medical Oncology · doi:10.1007/s12032-011-9944-6 · Cited by 5
Nandipati, B. L., & Devarakonda, N. (2023) · The Imaging Science Journal · doi:10.1080/13682199.2023.2183313 · Cited by 4
Chan, S.-K., Choi, C., & Lee, V. H.-F. (2022) · Cancers · doi:10.3390/cancers14143362 · Cited by 4
Zimpfer, A., Polak, A., Bier, A., Kundt, G., Kölbel, J., Prall, F., Virchow, J. C., Jr., & Erbersdobler, A. (2013) · Open Journal of Pathology · doi:10.4236/ojpathology.2013.33019 · Cited by 4
Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System
Dawe, D. E., & Ellis, P. M. (2012) · Journal of Personalized Medicine · doi:10.3390/jpm2030077 · Cited by 4
Metadata
- Authors
- Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., & Shepherd, F. A.
- Affiliations
- University of Turin (IT)
- Indiana University Indianapolis (US)
- The University of Texas MD Anderson Cancer Center (US)
- Eli Lilly (United States) (US)
- Eli Lilly (Germany) (DE)
- Eli Lilly (Canada) (CA)
- University of Toronto (CA)
- Corresponding author
- Scagliotti, Giorgio
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-02-16
- Volume
- 14
- Issue
- 3
- Pages
- 253-263
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2139939379
- Cited by
- 690
- References
- 51
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 10 · 2023: 15 · 2022: 21 · 2021: 15 · 2020: 27 · 2019: 29 · 2018: 30 · 2017: 42 · 2016: 46 · 2015: 41 · 2014: 69 · 2013: 72 · 2012: 71
- FWCI
- 72.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- pemetrexed, non-small cell lung cancer, tumor histology, squamous cell carcinoma, docetaxel, overall survival, progression-free survival, predictive biomarkers
- MeSH terms
- Pemetrexed, Docetaxel, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Randomized Controlled Trials as Topic, Taxoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
